Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase B domain-containing protein 2 (PLBD2) is a human lysosomal protein predicted to belong to the phospholipase B enzyme family, although its physiological substrate and precise biological function remain unconfirmed[3][1][2]. Structurally, it is an N-terminal nucleophile (NTN) hydrolase, sharing features with certain amidases and peptidases, and requires post-translational modifications including signal peptide cleavage, glycosylation, and proteolytic processing for maturation and lysosomal targeting[1][2]. PLBD2 is expressed in multiple tissues, including kidney and brain, and localizes primarily to the lysosome[5][2][3]. While mutations in the gene may theoretically contribute to lysosomal storage disorders, no definitive clinical phenotype has been ascribed[1]. The gene has several paralogs, notably PLBD1, and evidence suggests these enzymes diverged significantly following an ancient gene duplication event[1][3]. Despite extensive conservation of functional motifs, the actual activity and natural substrate of PLBD2 remain largely undetermined, and there are currently no known drugs or therapies that target this protein[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phospholipase B domain-containing protein 2 (PLBD2).